Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ

Conclusions: Four weeks of neoadjuvant lapatinib in patients with HER2-positive DCIS resulted in inhibition of HER2 and RAS/MAPK signaling pathway.Trial registration: 2008-004492-21 (Registered June 25th 2008).

http://breast-cancer-research.com/content/16/4/R76

Source: Breast Cancer Research - September 4, 2014 Category: Cancer & Oncology Authors: Laura EstévezAna Suarez-GauthierElena GarcíaCristina MiróIsabel CalvoMaría Fernández-AbadMercedes HerreroManuel MarcosCristina MárquezFernando Lopez RíosSofía PereaManuel Hidalgo Source Type: research